ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Hidradenitis suppurativa. Response to treatment with infliximab].

INTRODUCTION: Hidradenitis suppurativa is a chronic inflammatory disease that runs in outbreaks with painful lesions, fistulas and scars in axillae, groins, buttocks, and perianal and submammary regions. Among multiple drug therapies available, infliximab, usually employed in dermatology to control psoriasis, has shown its efficacy in the past five years.

PATIENTS AND METHOD: It is a prospective, observational study to determine the efficacy and safety of infliximab in the treatment of hidradenitis suppurativa. We selected three women with a history of hidradenitis suppurativa of more than 10 years, with involvement of at least two anatomic locations that was recalcitrant to conventional therapies. Each patient received infliximab at a dose of 5mg/kg/infusion on weeks 0, 2, 6 and every 8 weeks thereafter.

RESULTS: Two of the three patients showed mild to moderate improvement of their disease while the third patient did not improve. We can highlight the variability of the results observed in these three patients. Adverse effects were generally mild and well tolerated by the three patients. Despite this, two patients withdrew the therapy due to loss of efficacy in one case and the development of generalized arthalgias in the other case.

CONCLUSIONS: Treatment of hidradenitis supurativa with infliximab constitutes a moderately useful alternative in some cases.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app